依奇珠单抗治疗活动性非放射学中轴型脊柱关节炎52周随机对照试验中功能与健康的改善
COAST-X 研究在活动性非放射学中轴型脊柱关节炎患者中比较依奇珠单抗每4周或每2周与安慰剂治疗52周对自报功能和健康的影响。结果显示依奇珠单抗在SF-36生理组分摘要评分、ASAS健康指数和EQ-5D-5L方面优于安慰剂,第16周和第52周均有改善,两种给药方案间无临床意义差异。
要点
- 依奇珠单抗每4周或每2周治疗可改善非放射学中轴型SpA患者SF-36生理组分评分。
- 每2周组更多患者ASAS健康指数改善≥3,每4周组更多患者达到ASAS≤5的良好健康状态。
- EQ-5D-5L改善在第16周优于安慰剂并维持至第52周,两种剂量间无临床意义差异。
核心结论
- 在活动性非放射学中轴型SpA患者中,依奇珠单抗在第16周和第52周改善自报功能和健康方面优于安慰剂。
研究设计与样本
- COAST-X为52周随机对照试验,患者按1:1:1随机接受依奇珠单抗80 mg皮下每4周、每2周或安慰剂治疗。
- 评估终点包括SF-36健康调查、ASAS健康指数和EQ-5D-5L健康效用描述系统。
主要发现
- 与安慰剂相比,依奇珠单抗每4周组SF-36生理组分摘要评分从基线4.7改善至8.9(P < 0.05),每2周组改善至9.3(P < 0.01)。
- 第16周和第52周在生理功能、生理角色和躯体疼痛领域观察到最大改善。
- 每2周组更多患者从基线至第16周和第52周ASAS健康指数改善≥3(P < 0.05)。
- 每4周组更多患者在第16周和第52周ASAS健康指数达到≤5的良好健康状态(P < 0.05)。
- 第16周依奇珠单抗组EQ-5D-5L改善优于安慰剂(每4周0.11、每2周0.19 vs 安慰剂0.17,P < 0.05),第52周保持一致。
关键数值与推荐
- SF-36生理组分摘要评分:依奇珠单抗每4周从基线4.7改善至8.9(P < 0.05),每2周改善至9.3(P < 0.01)。
- ASAS健康指数改善≥3:每2周组比例高于安慰剂(P < 0.05)。
- ASAS健康指数≤5(良好健康状态):每4周组比例高于安慰剂(P < 0.05)。
- EQ-5D-5L第16周:每4周0.11、每2周0.19,安慰剂0.17(P < 0.05)。
临床怎么用
- 依奇珠单抗可用于改善活动性非放射学中轴型SpA患者的自报功能和健康,每4周与每2周方案疗效无临床意义差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the effect of ixekizumab on self-reported functioning and health in patients with active nonradiographic axial spondyloarthritis (SpA). METHODS: COAST-X was a randomized, controlled trial conducted in patients with nonradiographic axial SpA over 52 weeks. Participants were randomized at a ratio of 1:1:1 to receive 80 mg of ixekizumab subcutaneously every 4 weeks or 2 weeks or placebo for 52 weeks. Self-reported functioning and health end points included the Medical Outcomes Study Short Form 36 (SF-36) health survey, Assessment of Spondyloarthritis International Society (ASAS) health index, and European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) health-utility descriptive system. RESULTS: Compared to placebo, ixekizumab treatment resulted in improvement of SF-36 physical component summary scores from baseline, with a score of 4.7 improving to 8.9 with ixekizumab therapy every 4 weeks (P < 0.05) and a score of 9.3 with ixekizumab therapy every 2 weeks (P < 0.01); the greatest improvements were observed in the domains of physical functioning, role-physical, and bodily pain at weeks 16 and 52. A higher proportion of patients receiving ixekizumab therapy every 2 weeks reported ≥3 improvements based on the ASAS health index from baseline to weeks 16 and 52 (P < 0.05). Significantly more patients receiving ixekizumab every 4 weeks reported improvements in "good health status" on the ASAS health index (ASAS score of ≤5) at weeks 16 and 52 (P < 0.05). Patients receiving ixekizumab reported improvements on the EQ-5D-5L compared to those who received placebo at week 16 (0.11 versus 0.17 for patients receiving treatment every 4 weeks and 0.19 for patients receiving treatment every 2 weeks; P < 0.05), which remained consistent at week 52. There were no clinical meaningful differences in responses based on the ixekizumab dosing regimen for patients who received ixekizumab therapy every 2 weeks or every 4 weeks. CONCLUSION: In patients with nonradiographic axial SpA, therapy with ixekizumab was superior to placebo in the improvement of self-reported functioning and health at weeks 16 and 52.
引用
- Walsh JA, Magrey MN, Baraliakos X, et al. Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52-Week, Randomized, Controlled Trial. Arthritis Care Res (Hoboken). 2022. PMID: 33044756. doi:10.1002/acr.24482
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。